glp-1 receptor agonists are contraindicated in increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal Updated Ranking and Side Effects

How GLP-1 Agonists Create Appetite Suppression Metformin Cannot Match GLP-1 receptor agonists like semaglutide and tirzepatide bind directly to GLP-1 receptors throughout the body, triggering signals that slow stomach emptying, increase satiety, and reduce hunger signaling from the brain to the gut

VIP For research use only

Furthermore, GPX4 is the downstream target of Kruppel-like factor11 (KLF11)

The final reality: doses above 1.0mg daily do not produce proportional increases in melanogenesis

Yes, but only in gastroenterology

"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial." JAMA , 331(1), 38-48